XTLB - XTL BIOPHARMACEUTICALS LTD

2.45
-0.030   -1.224%

Share volume: 4,820
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
$2.48
-0.03
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.20%
1 Month
314.55%
3 Months
153.10%
6 Months
91.41%
1 Year
92.91%
2 Year
0.41%
Key data
Stock price
$2.45
P/E Ratio 
0.00
DAY RANGE
$2.37 - $2.60
EPS 
N/A
52 WEEK RANGE
$0.53 - $2.96
52 WEEK CHANGE
$92.91
MARKET CAP 
15.203 M
YIELD 
N/A
SHARES OUTSTANDING 
5.449 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.58
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,927
AVERAGE 30 VOLUME 
$13,112
Company detail
CEO: Shlomo S. Shalev
Region: US
Website: xtlbio.com
Employees: 8
IPO year: 2005
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.

Recent news